Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study

Autor: Antonela Matana, Joško Bezić, Sendi Kuret, Marina Piljić Burazer, Merica Glavina Durdov, Suzana Mladinov
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Adult
Male
Lung adenocarcinoma
medicine.medical_specialty
Pathology
Histology
Lung Neoplasms
medicine.medical_treatment
Adenocarcinoma of Lung
Single Center
Gastroenterology
Pathology and Forensic Medicine
03 medical and health sciences
0302 clinical medicine
Internal medicine
Carcinoma
Non-Small-Cell Lung
Biopsy
Antineoplastic Combined Chemotherapy Protocols
medicine
lcsh:Pathology
Humans
Stage (cooking)
Aged
Neoplasm Staging
Platinum-based chemotherapy
Aged
80 and over
Chemotherapy
Predictive marker
medicine.diagnostic_test
Performance status
business.industry
Research
General Medicine
Middle Aged
medicine.disease
Endonucleases
Prognosis
Radiation therapy
DNA-Binding Proteins
ERCC1
030104 developmental biology
030220 oncology & carcinogenesis
Adenocarcinoma
Female
Cisplatin
business
lcsh:RB1-214
Zdroj: Diagnostic Pathology
Diagnostic Pathology, Vol 14, Iss 1, Pp 1-8 (2019)
Popis: Background High ERCC1 expression is thought to be related with resistance to chemotherapy based on platinum. The aim of this study was to present our institutional observations regarding to the association of ERCC1 and overall survival (OS) of the lung adenocarcinoma patients who received chemotherapy based on platinum. Material/methods A total of 253 lung adenocarcinoma patients in all TNM stages were retrospectively investigated. The diagnosis was based on small biopsy samples obtained during bronchoscopy. Depending on the TNM stage of the disease and clinical condition, patients received only the chemotherapy based on platinum, or in combination with radiotherapy or surgery. Tissue sample for ERCC1 immunohistochemical analysis was sufficient in 129 patients. Low from high ERCC1 expression was separated by the semi-quantitative H-score median. Results High ERCC1 expression was found in 47.3% patients, and was correlated with higher TNM (p = 0.021), tumor enlargement (p = 0.002), positive lymph nodes (p = 0.001), positive distant metastasis (p = 0.005), and higher relative risk of death (p p = 0.023). Longer OS was strongly associated with a low ERCC1 expression, not only in the group of patients in TNM stage I-III, who were treated with combination of chemotherapy with surgery or radiotherapy (p = 0.002), but also in the group of patients in TNM stage IV who received only chemotherapy based on platinum (p Conclusions ERCC1 expression in lung adenocarcinoma is a useful prognostic marker and moreover, a useful predictive marker in patients receiving chemotherapy based on platinum in all stages of the disease.
Databáze: OpenAIRE
Externí odkaz: